Literature DB >> 33278866

Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia.

Emmaline Zantua Fernando1, Jeryl Ritzi Tan Yu1, Salvador Miclat Abad Santos2, Roland Dominic Go Jamora1,3,4.   

Abstract

Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Entities:  

Keywords:  Adverse drug reactions; COVID-19; Hydroxychloroquine; Involuntary movements; Myoclonus; Tremors

Year:  2020        PMID: 33278866     DOI: 10.14802/jmd.20091

Source DB:  PubMed          Journal:  J Mov Disord        ISSN: 2005-940X


  2 in total

Review 1.  Safety profile of COVID-19 drugs in a real clinical setting.

Authors:  Mei Nee Chiu; Maitry Bhardwaj; Sangeeta Pilkhwal Sah
Journal:  Eur J Clin Pharmacol       Date:  2022-01-28       Impact factor: 3.064

Review 2.  New-Onset Movement Disorders Associated with COVID-19.

Authors:  Pedro Renato P Brandão; Talyta C Grippe; Danilo A Pereira; Renato P Munhoz; Francisco Cardoso
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2021-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.